Trial Profile

A Phase II Study of ARQ 501 [beta lapachone] in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Beta lapachone (Primary) ; Gemcitabine
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use
Sponsors ArQule

Most Recent Events

08 Jan 2009 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
02 Nov 2007 Interim results have been reported: final results expected before the end of 2007.
22 Mar 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com